CN105254482A - New varied triterpenoid compound and preparation method and medical application thereof - Google Patents
New varied triterpenoid compound and preparation method and medical application thereof Download PDFInfo
- Publication number
- CN105254482A CN105254482A CN201510771470.2A CN201510771470A CN105254482A CN 105254482 A CN105254482 A CN 105254482A CN 201510771470 A CN201510771470 A CN 201510771470A CN 105254482 A CN105254482 A CN 105254482A
- Authority
- CN
- China
- Prior art keywords
- compound
- ldl
- extract
- preparation
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a new varied triterpenoid compound and a preparation method and medical application thereof. The compound is reported for the first time and is a varied triterpenoid compound novel in structure, and can be extracted from dried leaves of lawsonia inermis and obtained through separation and purification. As is proved by the study, the compound can remarkably improve the cell activity of human umbilical vascular endothelial cells injured by ox-LDL and has the effect of inhibiting HUVEC injuries induced by ox-LDL, and the effect is in dose dependency. The prompting compound (I) can achieve the endothelium protecting effect by inhibiting HUVEC apoptosis induced by ox-LDL, and the compound can be developed into endothelium protecting drugs.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to be separated a kind of assorted note compounds with endotheliocyte provide protection obtained and preparation method thereof from the dry leave of Lawsonia inermis.
Background technology
Lawsonia inermis Lawsoniainermis, Lythraceae Lythtaceae Lawsonia inermis platymiscium, be again Lawsonia inermis, nail leaf, hand first wood, wooden, the Gan Jiashu of nail, its leaf, flower, fruit, seed can use as traditional Chinese medicine.Lawsonia has good curative effect to diarrhoea, dysentery, leprosy, scabies; Flower can be used to treatment headache, fever, allergy, anaemia, insomnia etc.; Seed is effective to fever, insomnia, dysentery, diarrhoea and amentia; Bark can treat spleen enlargement and dermatosis chronic disease; Root can treat leprosy.Lawsonia inermis main product, in the torrid zone, subtropics, is extensively present in the Middle East, north African, also has cultivation in southern areas such as China Guangdong, Guangxi, Fujian, Taiwan.As far back as 304 years Christian eras Shanxi check to be contained in " southern vegetation shape " book and be called Lawsonia inermis, be called Hina or Mihid in 1964 version " Uygur medicine medicinal materials ".
Modern study finds that Lawsonia inermis contains polytype compounds such as quinone, Phenylpropanoid Glycosides, flavones, triterpene, phenolic acid and lipid acid.
Pharmacological research shows that Lawsonia inermis has the pharmacologically active widely such as antibacterial, antitumor, anti-oxidant, parasiticide, has very large value of exploiting and utilizing, is therefore subject to the extensive concern of scholars.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry leave of Lawsonia inermis, be separated a kind of assorted note compounds with endotheliocyte provide protection obtained and preparation method thereof.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula,
The preparation method of described compound (I), comprise following operation steps: the dry leave of Lawsonia inermis is pulverized by (a), extract with 80 ~ 90% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 80% ethanol elution, 8 column volumes, collect 80% ethanol eluate, concentrating under reduced pressure obtains 80% ethanol elution thing medicinal extract; C in () step (b), 80% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,50:1,35:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 25:1,15:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 75%, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, described macroporous resin is AB-8 type macroporous adsorbent resin.
Further, described alcohol heat reflux extracts the alcohol concn adopted is 85%.
A kind of pharmaceutical composition, the described compound (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
The application of described compound (I) in the medicine preparing endotheliocyte protection.
The application of described pharmaceutical composition in the medicine preparing endotheliocyte protection.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that the theoretical ECD value of compound (I) compares with experiment ECD value.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: compound (I) is separated preparation and structural identification
Reagent source: ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Preparation method: the dry leave (8kg) of Lawsonia inermis is pulverized by (a), (25L × 3 time) are extracted with 85% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (3L), use sherwood oil (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated propyl carbinol (3L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (359g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract AB-8 type macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, use 80% ethanol elution, 8 column volumes again, collect 80% ethanol eluate, concentrating under reduced pressure obtains 80% ethanol elution thing medicinal extract (138g); C in () step (b), 80% ethanol elution medicinal extract purification on normal-phase silica gel is separated, successively with volume ratio be 80:1 (8 column volumes), the methylene chloride-methanol gradient elution of 50:1 (8 column volumes), 35:1 (6 column volumes), 15:1 (8 column volumes) and 1:1 (5 column volumes) obtains 5 components; D component 4 (32g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 25:1 (8 column volumes), the methylene chloride-methanol gradient elution of 15:1 (10 column volumes) and 5:1 (6 column volumes) obtains 3 components; E in () step (d), component 2 (17g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 75%, collect 8-10 column volume elutriant, elutriant concentrating under reduced pressure obtains pure compound (I) (29mg).
Structural identification: HR-ESIMS shows [M+Na]
+for m/z359.1108, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
17h
20o
7, degree of unsaturation is 8.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 600MHz): H-2 (6.32, s), H-5 (3.81, d, J=15.0), H-5 (3.14, d, J=15.0), and H-7 (5.83, s), H-9 (2.36, d, J=12.4), H-9 (1.41, d, J=12.4), H-11 (4.91, s), H-15 (1.66, s), and H-16 (1.37, s), 1-OH (16.17, s), 4-OH (9.57, s), and 10-OH (5.08, s), 11-OH (6.16, s), 3-OCH
3(3.87, s); Carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 125MHz): 158.4 (C, 1-C), 98.2 (CH, 2-C), 152.5 (C, 3-C), 137.6 (C, 4-C), 30.3 (CH
2, 5-C), 145.1 (C, 6-C), 134.8 (CH, 7-C), 197.8 (C, 8-C), 46.1 (CH
2, 9-C), 67.1 (C, 10-C), 97.7 (CH, 11-C), 198.7 (C, 12-C), 114.2 (C, 13-C), 121.9 (C, 14-C), 21.1 (CH
3, 15-C), 17.1 (CH
3, 16-C), 56.0 (CH
3, 3-OCH
3); Carbon atom mark is see Fig. 1.Infrared spectra shows that this compound contains oh group (3440cm
-1); In addition this compound has uv-absorbing in 371 and 291nm, illustrates containing many conjugated structures.
13cNMR spectrum and hsqc spectrum show 17 carbon signals, be respectively three methyl (methoxyl group), two methylene radical, three methynes (two alkene carbon and with individual containing oxygen carbon) and nine quaternary carbon (two ketone carbonyls, three containing oxygen alkene carbon, three alkene carbon and one are containing oxygen quaternary carbon).In addition, olefinic proton signals δ H6.32 (s, H-2), and six olefinic carbon signals δ C158.4 (C, 1-C), 98.2 (CH, 2-C), 152.5 (C, 3-C), 137.6 (C, 4-C), 114.2 (C, 13-C) and 121.9 (C, 14-C), show that this compound contains one five benzene ring structure replaced.In HMBC spectrum, hydroxyl proton (δ H16.17, s, 1-OH) and C-1, C-2, the dependency of C-13 and δ C198.7 (C, 12-C) shows that carbonyl carbon (C-12) is connected with the C-13 position of phenyl ring, and this compound also demonstrates this conclusion in the uv-absorbing of 371 and 291nm.In HMBC spectrum, hydroxyl proton δ H9.57 (1H, s, 4-OH) and δ C152.5 (C, 3-C), 137.6 (C, 4-C) and 121.9 (C, 14-C); Methoxyl group proton δ H3.87 (s, 3-OCH
3) and C-3; And the dependency of H-2 and C-3 shows that hydroxyl and methoxyl group lay respectively on C-4 and C-3 position.Remove seven carbon of phenyl ring and methoxyl group, remaining 10 carbon atoms define a ten-ring monoterpene structure.In addition, this compound contains one three and replaces carbon double bond (δ C145.1; δ C134.8, δ H5.83, s); In HMBC spectrum, the above-mentioned inference of the relevance verification of H-7 and C-5 (δ C30.3), C-8 (δ C197.8) and C-9 (δ C46.1).Chemical shift containing oxygen carbon C-10 and C-11 (δ C67.1 and 97.7) shows that they all contain oh group.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and ROESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
Human umbilical vein endothelial cells pearl (HUVEC) is provided by Shanghai Wu Li Bioisystech Co., Ltd cell bank.Compound (I) is made by oneself, and HPLC normalization method purity is greater than 98%.RPMI-1640 substratum, MTT, dimethyl sulfoxide (DMSO) are all purchased from Sigma company.Foetal calf serum is purchased from HyCLone company.FITC marks goat anti-rabbit igg, the anti-human factor Ⅷ related antigen of rabbit is purchased from Beijing Bo Aosen Bioisystech Co., Ltd.MDA reagent box for detecting content is purchased from Nanjing and builds up biological study institute.AnnexinV-FITC apoptosis detection kit is purchased from Centrebio company.Ethylenediamine tetraacetic acid (EDTA) (EDTA) is purchased from Guangzhou Wei Jia Science and Technology Ltd..
DK-8AD type electric heating constant temperature tank (Shanghai Yiheng Scientific Instruments Co., Ltd), ER-120A type electronic analytical balance (Shimadzu Corporation), 6219 type electronics pH meters (Shanghai Ren Shi Electronics Co., Ltd.), high speed low temperature centrifugal machine (Sigma company), L420 table-type low-speed self-poise whizzer (Xiang Yi whizzer Instrument Ltd.), SYC-2101 horizontal shaker (its woods Bel instrument manufacturing company limited), 1000 μ L micro sample-adding rifle × 1, 20-100 μ L micro sample-adding rifle × 1, 1-20 μ L micro sample-adding rifle × 1 (French Ji Ersen company), CO
2(incubator Heraeus company), super clean bench (safe and sound company of Su Jing group), inverted phase contrast microscope (German Lycra), microplate reader (Sigma company), FACSCaLibur (flow cytometer).
Two, test method
1, the cultivation of huve cell
1.1 culture condition
The HUVEC cell strain newly bought is inoculated in the RPMI-1640 substratum containing 10% foetal calf serum.Be placed in 37 DEG C, 5%CO
2in incubator, within every 2 days, change 1 subculture.
1.2 passage
Getting one bottle of HUVEC observation of cell under inverted phase contrast microscope, as grown up to fine and close individual layer, can go down to posterity; Shaken gently by culturing bottle for several times, suspended and floated over the fragment of cell surface, then poured out together with nutrient solution, draw 2 ~ 3mLPBS liquid and add in culturing bottle, hypsokinesis of vibrating gently is gone, and repeats 3 times; Add 1mL0.25% pancreatin, be limited can cover at the bottom of bottle, rotate culturing bottle, make moistening whole cellular layer, put 37 DEG C of digested 2 ~ 3min of incubator, till oneself contraction of cell to be confirmed becomes bowlder; Add 1mL nutrient solution in culturing bottle, stop digestion, draw nutrient solution with suction pipe and repeatedly blow and beat bottle parietal cell gently, make it to depart from from bottle wall to form cell suspension, inject centrifuge tube centrifugal (800r/min, 5min) abandoning supernatant afterwards; Add 3mL nutrient solution in centrifuge tube, draw nutrient solution with suction pipe and blow and beat gently for several times, make cell suspending weight, then press 1:3 or 1:4 and distribute Secondary Culture; Be placed in 37 DEG C, 5%CO in incubator
2cultivate in thermostat container, after 24h, change liquid, within usual 3-4 days, can individual layer be formed, now just interchangeable maintenance medium for experiment.
The counting of 1.3HUVEC
First get cell suspension 50 μ L to be measured to instill in cell counting count board, by white blood cell count(WBC) method, under low power lens, count the total cellular score in 4 block plaid of 4 jiaos, then with following formulae discovery cell concn: viable count/4 × 10 in 4 block plaid
4=cell count/mL
2, the qualification of huve cell
Sterile cover slips 1cm × 1cm is placed, by endotheliocyte suspension inoculation on cover glass, when endotheliocyte grows to converging state in 6 well culture plates, take out cover glass, with PBS flush cover slide, put into 100% acetone and fix 15min, rinse 3 times with PBS, each 2min, drip the H of 3%
2o
2incubated at room 8min, PBS rinse 3 times, each 2min, drip rabbit anti-human boron factor monoclonal antibodies (1:100), another cover glass do not add primary antibodie and make negative control 4 DEG C and spend the night.Next day, rinse 3 times with PBS, each 2min, drip the goat anti-rabbit igg of FITC mark one note, hatch 60min for 37 DEG C, rinse 3 times with PBS, each 2min, fluorescence microscopy Microscopic observation is also taken pictures.
3, the cytoactive of MTT colorimetric method for determining HUVEC is utilized
3.1 utilize MTT colorimetry to observe different dense compound (I) to the impact of huve cell activity
3.1.1 Secondary Culture
By HUVEC by 2 × 10
4the density of/mL is with the RPMI-1640 culture medium inoculated containing 10%FBS in 96 orifice plates, and 200 μ L are planted in every hole.
3.1.2 to divide into groups dosing
After passage cell cultivates 24h, with the RPMI-1640 substratum compounding pharmaceutical containing 10%FBS, cell is divided into 6 groups at random: control group (control), compound (I) 5 μ g/mL group, compound (I) 10 μ g/mL group, compound (I) 20 μ g/mL group, compound (I) 40 μ g/mL group, compound (I) 80 μ g/mL group, hole, every hole 6.Continue cultivation after 48 hours, mtt assay detects cytoactive.
3.1.3MTT method detects
Add oneself MTT solution of preparing of 20 μ L directly to every hole, hatch 4h for 37 DEG C, exhaustion supernatant, then adds 150 μ LDMSO.After abundant dissolving to be crystallized, microplate reader is utilized to measure OD value at wavelength 490nm place.
3.2 utilize MTT colorimetry to observe different concns ox-LDL to the impact of huve cell activity
3.2.1 Secondary Culture: the same.
3.2.2 to divide into groups dosing
After cell cultures 24h, with the RPMI-1640 substratum compounding pharmaceutical containing 10%FBS, cell is divided into 6 groups at random: control group (control), ox-LDL (for self-control) 10 μ g/mL groups, ox-LDL20 μ g/mL group, ox-LDL40 μ g/mL group, ox-LDL80 μ g/mL group, ox-LDL160 μ g/mL group, hole, every hole 6.Continue cultivation 24 hours, mtt assay detects cytoactive.
The intervention effect that 3.3 utilize MTT colorimetry to observe compound (I) induces huve cell to damage to ox-LDL
3.3.1 Secondary Culture: the same.
3.3.2 to divide into groups dosing
After cell cultures 24h, with the RPMI-1640 substratum compounding pharmaceutical of 10%FBS, cell is divided into 6 groups at random: control group (control), ox-LDL50 μ g/mL group, ox-LDL50 μ g/mL+ compound (I) 5 μ g/mL group, ox-LDL50 μ g/mL+ compound (I) 10 μ g/mL group, hole, ox-LDL50 μ g/mL+ compound (I) 20 μ g/mL every hole 6.Continue cultivation after 24 hours, mtt assay detects cytoactive.
4, utilizing Flow Cytometry to observe compound (I) induces the intervention of huve cell apoptosis to do to ox-LDL
4.1 use Secondary Culture
By HUVEC by 2 × 10
5the density of/mL is with the RPMI-1640 culture medium inoculated containing 10%FBS in 6 orifice plates, and 1500 μ L are planted in every hole.
4.2 grouping dosings
After cell cultures 24h, with RPMI-1640 serum free medium serum deprivation 24h, cell is made to enter stationary state.With containing RPML-1640 blood serum medium compounding pharmaceutical, cell is divided into 5 groups at random: control group (control), ox-LDL50 μ g/mL group, ox-LDL50 μ g/mL+ compound (I) 5 μ g/mL group, ox-LDL50 μ g/mL+ compound (I) 10 μ g/mL group, the every hole of ox-LDL50 μ g/mL+ compound (I) 20 μ g/mL adds 1mL pastille substratum.
4.3 operation steps
After dosing, 12h draws materials, and cell culture fluid sucking-off in centrifuge tube, PBS washs attached cell once, with pancreatin cell dissociation buffer peptic cell.After cell dissociation gets off, transfer in centrifuge tube, PBS washes three times (centrifugal 10 minutes of 1000g).Add 200 μ L binding buffer liquid, re-suspended cell.Add 10 μ LAnnexinv-FITC, 10 μ LPI staining fluids mix gently.Room temperature lucifuge hatches 15 minutes, upper machine testing apoptosis in 30 minutes.
5, statistical analysis
Adopt SPSS13.0 to add up a software to analyze, result is expressed as: mean scholar standard deviation
.When variance is neat, two groups are compared and adopt LSD, to compare more uses Dunnett to check as organized with control group, when heterogeneity of variance, and employing WeLch robust iterative, then adopt T3 method to compare between two.P<0.05 indicates statistical significance.
Three, result and conclusion
1, different concns compound (I) is on the impact of HUVEC cell viability
Compound (I) medicine is in certain its pharmacological action of concentration range competence exertion, and different cell systems also can be different to the susceptibility of medicine.For this reason, the drug level scope of experiment is first determined with mtt assay.Result is as table 1 (VS control group
#p<0.01) show, the effects of action of compound (I) Human Umbilical Vein Endothelial Cells of different concns is different, and drug level (5 ~ 20 μ g/mL) cytoactive of low dosage compares with control group, does not have significant difference.40 μ g/mL act on 48 hours later cell vigor and have dropped about 50%, and 80 μ g/mL act on 48 hours later cell vigor and have dropped 70%, compare and have significant difference (P<0.01), create certain toxic side effect with control group.Therefore this tests compound (I) concentration used is 5,10,20 μ g/mL, to get rid of the toxic action of medicine self to cell.
2, different concns ox-LDL is on the impact of huve cell vigor
Due to the difference of Ox LDL degree of oxidation, the cytotoxicity scope of Ox LDL can be different.Therefore we first adopt MTT to determine the cytotoxic scope of ox-LDL.Result is as table 2 (VS control group
*p<0.05
#p<0.01), shown in, different concns ox-LDL is different on the impact of HUVEC cytoactive.Compared with control group, 10 μ g/mL groups have the trend promoting that HUVEC cytoactive increases, but compare with control group and do not have significant difference (P>0.05); 20 ~ 100 μ g/mL respectively organize endothelial cell activity to be increased with concentration and reduces, and compares have significant difference (P<0.05 or P<0.01) with control group.
3, compound (I) induces the intervention effect of huve cell damage to ox-LDL
Result is as table 3 (VS.ox-LDLgroup
#p<0.01) shown in, the cytoactive that ox-LDL (50 μ g/mL) organizes declines, compare with control group and have significant difference (P<0.01), illustrate that ox-LDL group cytoactive significantly reduces, ox-LDL (50 μ g/mL) has damaging action to normal HUVEC.The cytoactive of compound (I) various dose group is all higher than ox-LDL group, statistical significance (P<0.01) is had with ox-LDL group comparing difference, illustrate that the cytoactive of these three dosage groups is significantly higher than ox-LDL group, the HUVEC damage that prompting compound (I) can suppress ox-LDL to induce.The cytoactive of compound (I) 10 μ g/mL and compound (I) 20 μ g/mL group, higher than compound (I) 5 μ g/mL group, compares with compound (I) 5 μ g/mL and has significant difference (P=0.01 or P<0.01).Compound (I) 20 μ g/mL cytoactive comparatively compound (I) 10 μ g/mL group has rising trend, but does not have significant difference (P=0.185).The Endothelium Protective effect of prompting compound (I) has dose-effect relationship within the specific limits.
4, compound (I) is on the impact of the huve cell apoptosis of ox-LDL induced damage
Each group of fluidic cell result display: the apoptosis rate difference of each group cell has statistical significance (P<0.01), the proliferation index of ox-LDL group obviously raises, compare with control group have significant difference (P<0.01) to illustrate ox-LDL (50 μ g/mL) has damaging action to normal HUVEC.The apoptosis rate of compound (I) various dose group is all lower than ox-LDL group, statistical significance (P<0.01) is had with ox-LDL group comparing difference, illustrate that the apoptosis rate of these three dosage groups is significantly lower than ox-LDL group, the HUVEC apoptosis that prompting compound (I) can suppress ox-LDL to induce.The apoptosis rate of compound (I) various dose group reduces gradually along with dosage raises, and between each group, difference has statistical significance (P<0.01).The results are shown in Table 4 (VSox-LDLgroup
#p<0.01).The protection of ecs effect of prompting compound (I) has dose-effect relationship within the specific limits.
Conclusion, this research adopts mtt assay to detect and finds that compound (I) can significantly improve the cell viability of the Human umbilical vein endothelial cells of ox-LDL damage, illustrates that it has the effect of the HUVEC damage suppressing ox-LDL induction.The two staining for flow cell art of further employing AnnexinV-FITC, PI detects apoptosis, and research finds that each concentration group compound (I) all significantly can reduce the HUVEC apoptosis of ox-LDL induction, and effect is dose-dependently.Prompting compound (I) realizes Endothelium Protective effect by suppressing the HUVEC apoptosis of ox-LDL induction.
Table 1 different concns compound (I) on the impact of HUVEC cell viability (
n=6)
| Group | Cell viability (%) |
| Control (control group) | 100.14±3.82 |
| Compound (I) 5 μ g/mL | 100.45±9.67 |
| Compound (I) 10 μ g/mL | 101.22±10.57 |
| Compound (I) 20 μ g/mL | 92.77±8.54 |
| Compound (I) 40 μ g/mL | 48.92±5.62 # |
| Compound (I) 60 μ g/mL | 32.79±2.54 # |
| Compound (I) 80 μ g/mL | 30.21±2.28 # |
| Fvalue | 298.51 |
| Pvalue | <0.01 |
Table 2ox-LDL on the impact of HUVEC cell viability (
n=6)
| Group | Cell viability (%) |
| Control (control group) | 100.02±5.01 |
| ox-LDL10μg/mL | 104.52±4.01 |
| ox-LDL20μg/mL | 93.484.77 * |
| ox-LDL40μg/mL | 86.96±5.78 # |
| ox-LDL60μg/mL | 64.22±3.58 # |
| ox-LDL80μg/mL | 57.21±2.54 # |
| Fvalue | 116.248 |
| Pvalue | <0.001 |
The different immunomodulator compounds of table 3 (I) to ox-LDL induce HUVEC damage intervention effect (
n=6)
| Group | Cell viability (%) |
| Control (control group) | 100.01±3.74 # |
| ox-LDL50μg/mL | 73.92±7.04 |
| Ox-LDL50 μ g/mL+ compound (I) 5 μ g/mL | 82.59±4.80 # |
| Ox-LDL50 μ g/mL+ compound (I) 10 μ g/mL | 90.01±3.70 # |
| Ox-LDL50 μ g/mL+ compound (I) 20 μ g/mL | 93.61±2.11 # |
| Fvalue | 29.15 |
| Pvalue | <0.001 |
Table 4 various dose compound (I) to ox-LDL induce HUVEC apoptosis effect (
n=3)
| Group | Apoptosis rate (%) |
| Control (control group) | 1.84±0.05 # |
| ox-LDL50μg/mL | 9.87±0.40 |
| Ox-LDL50 μ g/mL+ compound (I) 5 μ g/mL | 4.65±0.56 # |
| Ox-LDL50 μ g/mL+ compound (I) 10 μ g/mL | 3.67±0.23 # |
| Ox-LDL50 μ g/mL+ compound (I) 20 μ g/mL | 2.51±0.17 # |
| Fvalue | 274.678 |
| Pvalue | <0.001 |
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:9 in itself and excipient weight.
Embodiment 4
Prepared by oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula,
。
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry leave of Lawsonia inermis is pulverized by (a), extract with 80 ~ 90% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 6 column volumes, then use 80% ethanol elution, 8 column volumes, collect 80% ethanol eluate, concentrating under reduced pressure obtains 80% ethanol elution thing medicinal extract; C in () step (b), 80% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 80:1,50:1,35:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 25:1,15:1 and 5:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, be the methanol aqueous solution isocratic elution of 75% by concentration expressed in percentage by volume, collect 8 ~ 10 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is AB-8 type macroporous adsorbent resin.
4. the preparation method of compound according to claim 2 (I), is characterized in that: it is 85% that described alcohol heat reflux extracts the alcohol concn adopted.
5. a pharmaceutical composition, is characterized in that: the compound according to claim 1 (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
6. the application of compound according to claim 1 (I) in the medicine preparing endotheliocyte protection.
7. the application of pharmaceutical composition according to claim 5 in the medicine preparing endotheliocyte protection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510771470.2A CN105254482A (en) | 2015-11-12 | 2015-11-12 | New varied triterpenoid compound and preparation method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510771470.2A CN105254482A (en) | 2015-11-12 | 2015-11-12 | New varied triterpenoid compound and preparation method and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105254482A true CN105254482A (en) | 2016-01-20 |
Family
ID=55094482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510771470.2A Pending CN105254482A (en) | 2015-11-12 | 2015-11-12 | New varied triterpenoid compound and preparation method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105254482A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105461531A (en) * | 2016-01-12 | 2016-04-06 | 郑平珍 | Novel sesquiterpene compound and preparation method and medical application thereof |
| CN105622563A (en) * | 2016-04-08 | 2016-06-01 | 庄立 | Pharmaceutical composition of bromhexine hydrochloride and medical application thereof |
| CN106117235A (en) * | 2016-06-24 | 2016-11-16 | 丁俣汀 | The pharmaceutical composition of dipyridamole and the application in biological medicine thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003055861A1 (en) * | 2001-12-28 | 2003-07-10 | Pharmacia Italia Spa | Benzocyclodecane derivatives with antitumor activity |
-
2015
- 2015-11-12 CN CN201510771470.2A patent/CN105254482A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003055861A1 (en) * | 2001-12-28 | 2003-07-10 | Pharmacia Italia Spa | Benzocyclodecane derivatives with antitumor activity |
Non-Patent Citations (2)
| Title |
|---|
| 刘彬: "丹酚酸B对ox-LDL诱导人脐静脉内皮细胞凋亡干预作用的研究", 《中国优秀硕士论文全文数据库医药卫生科技辑》 * |
| 李倩等: "散沫花化学成分和生物活性研究进展", 《中国中药杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105461531A (en) * | 2016-01-12 | 2016-04-06 | 郑平珍 | Novel sesquiterpene compound and preparation method and medical application thereof |
| CN105622563A (en) * | 2016-04-08 | 2016-06-01 | 庄立 | Pharmaceutical composition of bromhexine hydrochloride and medical application thereof |
| CN106117235A (en) * | 2016-06-24 | 2016-11-16 | 丁俣汀 | The pharmaceutical composition of dipyridamole and the application in biological medicine thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105330716A (en) | New withanolides compound, and preparation method and medical application thereof | |
| CN105111269A (en) | Novel limonin compound as well as preparation method and medical application thereof | |
| CN105198893A (en) | Diterpenoid compounds for treating stomach cancer | |
| CN105418544A (en) | Protoilludane sesquiterpenoid compound, preparation method and medical applications thereof | |
| CN105254482A (en) | New varied triterpenoid compound and preparation method and medical application thereof | |
| CN105294616A (en) | New limonoids for protecting endothelial cells | |
| CN105418562A (en) | Diterpenoid compound used for treating the prostatic cancer and preparation method therefor | |
| CN105294665A (en) | Novel diterpene compound for neuroprotection | |
| CN105503556A (en) | Eremophilane type sesquiterpenoids and medical application thereof | |
| CN105153267A (en) | Novel withanolides compound, novel withanolides compound preparation method and medical application of novel withanolides compound | |
| CN105384750A (en) | Kauran diterpene compound for curing renal cancer | |
| CN105348361A (en) | Triterpene compound used for protecting endothelial cells | |
| CN105503871A (en) | Novel indole alkaloid compound and preparation method and medical application thereof | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105294723A (en) | Diterpenoid compound for treating breast cancer and preparation method thereof | |
| CN105418539A (en) | New meroterpenoid compound as well as preparation method and pharmaceutical application thereof | |
| CN105367536A (en) | Novel iridoid and preparation method and medical application thereof | |
| CN105503991A (en) | Limonin compound for treating breast cancer and preparation method of limonin compound | |
| CN105566427A (en) | Lanostane triterpene compound, and preparation method and medicinal use thereof | |
| CN105153263A (en) | New limonin compound as well as preparation method and medical application thereof | |
| CN105859671A (en) | Sesquiterpenoids for medicine and preparation method thereof | |
| CN105384721A (en) | Novel biphenyl cyclooctene lignin compound, and preparation method and application thereof | |
| CN105566438A (en) | Limonin compound for treating neuroglioma, and preparation method thereof | |
| CN105481936A (en) | Novel oleanane type triterpene compound and preparation method and medical application thereof | |
| CN105481874A (en) | Novel diterpene compound for treating ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 325016, Shaoxing City, Zhejiang province Zhuji Ruan Town soup Village Applicant after: Zhuang Li Address before: 325016 Zhejiang Province, Wenzhou city Ouhai District streets Quxi Road No. 26 reform Applicant before: Zhuang Li |
|
| COR | Change of bibliographic data | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160120 |